Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Receivables (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Receivables for 12 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables fell 54.42% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2025, down 54.42%, and an annual FY2024 reading of $4.2 million, up 22.47% over the prior year.
  • Receivables was $2.0 million for Q3 2025 at CytomX Therapeutics, down from $2.8 million in the prior quarter.
  • Across five years, Receivables topped out at $36.0 million in Q4 2022 and bottomed at $887000.0 in Q3 2021.
  • Average Receivables over 5 years is $5.5 million, with a median of $2.8 million recorded in 2025.
  • The sharpest move saw Receivables crashed 99.26% in 2021, then skyrocketed 2163.27% in 2022.
  • Year by year, Receivables stood at $1.6 million in 2021, then surged by 2163.27% to $36.0 million in 2022, then plummeted by 90.46% to $3.4 million in 2023, then rose by 22.47% to $4.2 million in 2024, then crashed by 51.72% to $2.0 million in 2025.
  • Business Quant data shows Receivables for CTMX at $2.0 million in Q3 2025, $2.8 million in Q2 2025, and $2.9 million in Q1 2025.